Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis

References

• Ayyappan S, Prabhakar D, Sharma N. 2013. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer. Anticancer Res 33:4139–4155
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
   PubMed Web of Science ®Google Scholar
• Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z. 2011. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: A meta-analysis. Eur J Clin Pharmacol 67:235–243
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, et al. 2013. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial. Lancet Oncol 14:627–637
   PubMed Web of Science ®Google Scholar
• Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, et al. 2014. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 15:894–904
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
   PubMed Web of Science ®Google Scholar
• Goss GD, O’Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, et al. 2013. Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J Clin Oncol 31:3320–3326
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S; Cochrane Collaboration. 2008. Cochrane Handbook for Systematic Reviews of Interventions. England: John Wiley & Sons
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. BMJ 327:557–560
   PubMed Web of Science ®Google Scholar
• Huang X, Gao P, Sun J, Chen X, Song Y, Zhao J, Xu H, Wang Z. 2015. Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis. Int J Cancer 136:21–33
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. 1996. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1–12
   PubMedGoogle Scholar
• Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D’Angelo SP, Kris MG, et al. 2011. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 6:569–575
   PubMed Web of Science ®Google Scholar
• Ku GY, Haaland BA, de Lima Lopes G Jr. 2012. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: The choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 70:231–238
   PubMed Web of Science ®Google Scholar
• Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, et al. 2013. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: Evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open 3 :e001802. doi: 10.1136/bmjopen-2012-001802
   PubMed Web of Science ®Google Scholar
• Lara PN, Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. 2008. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials. J Clin Oncol 26:463–467
   PubMed Web of Science ®Google Scholar
• Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS. 2014. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis. JAMA 311:1430–1437
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, et al. 2013. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol 14:490–499
   PubMed Web of Science ®Google Scholar
• Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, et al. 2010. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102:500–505
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, et al. 2009. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20:1667–1673
   PubMed Web of Science ®Google Scholar
• Luo HQ, Han L, Jiang Y. 2014. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev 15:5343–5348
   PubMedGoogle Scholar
• Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, et al. 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103–2114
   PubMed Web of Science ®Google Scholar
• Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, et al. 2011. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase II study. Ann Oncol 22:1358–1366
   PubMed Web of Science ®Google Scholar
• Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. 2000. Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement. Onkologie 23:597–602
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. 2015a. Esophageal and esophagogastric junction Cancers. Version 1. Available from: http://www.nccn.org/ [Accessed 1 Feb 2015]
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. 2015b. Gastric cancer. Version 1. Available from: http://www.nccn.org/ [Accessed 1 Feb 2015]
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. 2015c. Rectal cancer. Version 2. Available from: http://www.nccn.org/ [Accessed 1 Feb 2015]
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. 2015d. Colon cancer. Version 2. Available from: http://www.nccn.org/ [Accessed 1 Feb 2015]
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. 2014. Head and neck cancers. Version 2. Available from: http://www.nccn.org/ [Accessed 1 Feb 2015]
   Google Scholar
• Pang X, Wei W, Leng W, Chen Q, Xia H, Chen L, Li R. 2014. Radiotherapy for gastric cancer: A systematic review and meta-analysis. Tumour Biol 35:387–396
   PubMed Web of Science ®Google Scholar
• Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. 2013. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One 8:e83138. doi: 10.1371/journal.pone.0083138
   PubMed Web of Science ®Google Scholar
• Petty RD, Dahle-Smith A, Miedzybrodzka Z, Dutton SJ, Murray GI, Stevenson D, Massie D, et al. 2014. Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib inesophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG). J Clin Oncol 32:Abstr4016
   Google Scholar
• Qiu MZ, Xu RH. 2013. The progress of targeted therapy in advanced gastric cancer. Biomarker Res 1:32. doi: 10.1186/2050-7771-1-32
   PubMedGoogle Scholar
• Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, et al. 2010. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol 21:2213–2219
   PubMed Web of Science ®Google Scholar
• Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, et al. 2013. Results of docetaxel plus oxaliplatin (DOCOX) +/− cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study. Eur J Cancer 49:2823–2831
   PubMed Web of Science ®Google Scholar
• Tian W, Ding W, Kim S, Xu X, Pan M, Chen S. 2013. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis. Pancreatology 13:415–422
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi: 10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Villela DL, Santos VL. 2010. Evidence on the use of platelet-rich plasma for diabetic ulcer: A systematic review. Growth Factors 28:111–116
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, et al. 2013. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 14:481–489
   PubMed Web of Science ®Google Scholar